PENG With LFCB vs. ESP Blocks for Pediatric Hip Surgery

Phase 4RecruitingNCT07023094

Poznan University of Medical Sciences60 enrolled

Overview

This randomized controlled trial (RCT) compares the analgesic effectiveness of two regional anesthesia techniques-Pericapsular Nerve Group (PENG) block combined with Lateral Femoral Cutaneous Nerve Block (LFCB) versus Lumbar and Sacral Erector Spinae Plane Blocks (L-ESPB and S-ESPB)-in pediatric patients undergoing hip surgery.

Orthopedic hip procedures in pediatric patients, including osteotomies, arthroscopic interventions, and reconstructive surgeries, often result in significant postoperative pain. Effective analgesia is critical for reducing surgical stress, accelerating rehabilitation, and minimizing opioid use and associated side effects. Regional anesthesia techniques have gained attention for their opioid-sparing effects and enhanced recovery profiles. This randomized controlled trial aims to compare the analgesic effectiveness of two regional anesthetic approaches: \- The pericapsular nerve group (PENG) block is combined with the lateral fetal cutaneous nerve block (LFCB), targeting hip joint innervation directly and providing comprehensive sensory coverage. Lumbar and sacral erector spinae plane blocks (L-ESPB and S-ESPB) employ fascial plane techniques to deliver analgesia by diffusing local anesthetic around nerves innervating the hip region. This trial aims to establish the optimal regional anesthesia technique and determine the clinical benefits of using dexamethasone and dexmedetomidine as adjuvants. The results will guide clinicians toward evidence-based analgesic protocols in pediatric orthopedic hip surgery, potentially reducing opioid-related complications and improving patient recovery outcomes.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Hip Disease Hip Dysplasia Hip Arthropathy

Interventions

Ropivacaine 0.2% for PENG BlockDRUG

U-S guided PENG (0.4 mL/kg) with 0.2% ropivacaine

Ropivacaine 0.2% for LFCBDRUG

LFCB (0.1 mL/kg) with 0.2% ropivacaine

Ropivacaine 0.2% for L-ESPBDRUG

Lumbar ESPB (0.25ml/kg) with 0.2% ropivacaine

Eligibility

Sex: ALLMin age: 2 YearsMax age: 16 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Pediatric patients aged between 2 and 16 years. * Scheduled for elective orthopedic hip surgery, including: Osteotomies and Hip reconstruction surgeries * ASA (American Society of Anesthesiologists) physical status classification: I-III. * Written informed consent obtained from the patient's legal guardian(s). Exclusion Criteria: * Known allergy or hypersensitivity to any of the study medications * Presence of infection or inflammation at the intended injection site(s) of regional anesthesia. * Coagulopathy or bleeding disorders (including patients on anticoagulant therapy) that contraindicate nerve blocks. * Neurological disorders or peripheral neuropathies that could influence sensory or motor assessment of the lower limbs. * Cognitive impairment or behavioral disorders significantly affecting pain assessment accuracy or cooperation. * History of chronic opioid use or known substance abuse. * Severe systemic disease or condition compromising patient safety or interfering with study protocol adherence.

Locations (1)

Poznan University of Medical Sciences

Poznan, Poland

RECRUITING

Outcomes

Primary Outcomes

Total Opioid Consumption

Total opiate consumption after surgery

Time frame: 48 hours after surgery